Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia

Journal of Thrombosis and Thrombolysis

Volumn 43, Issue 2, 2017, Pages 224-232

  Gheldof, Damien ^a   Haguet, Hélène ^a   Dogné, Jean Michel ^b   Bouvy, Céline ^b   Graux, Carlos ^a   George, Fabienne ^a   Sonet, Anne ^a   Chatelain, Christian ^b   Chatelain, Bernard ^a   Mullier, François ^a,b  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b University of Namur   (Belgium)

Author keywords

Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Disseminated intravascular coagulation; Extracellular vesicles; Microparticles; Thrombosis; Tissue factor

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; THROMBIN; THROMBOPLASTIN;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD SAMPLING; CELL ISOLATION; COHORT ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; EXOSOME; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; RISK ASSESSMENT; THROMBIN GENERATION ASSAY; THROMBOSIS; TREATMENT DURATION; ULTRACENTRIFUGATION; VERY ELDERLY; YOUNG ADULT; ACUTE DISEASE; COMPLICATION; DISSEMINATED INTRAVASCULAR COAGULATION; LEUKEMIA; METABOLISM; PATHOLOGY; PHYSIOLOGY; RISK; TIME FACTOR;

ACUTE DISEASE; BIOMARKERS; BLOOD COAGULATION; COHORT STUDIES; DISSEMINATED INTRAVASCULAR COAGULATION; EXTRACELLULAR VESICLES; FEMALE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; RISK; THROMBIN; THROMBOSIS; TIME FACTORS;

EID: 85009230890     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-016-1471-z     Document Type: Article

References (40)

1. Ku GH, White RH, Chew HK, Harvey DJ, Zhou H, Wun T (2009) Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 113: 3911–3917. doi: 10.1182/blood-2008-08-175745
2. Kwaan HC, Rego EM (2010) Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia. Semin Thromb Hemost 36:917–924
3. Khorana AA (2013) Venous thromboembolism prevention in cancer outpatients. J Natl Compr Cancer Netw 11:1431–1438
4. Khorana AA, Dalal M, Lin J, Connolly GC (2013) Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer 119:648–655
5. Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, Colon J, Baker CH, Francis JL. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 6:1517–1524. doi: 10.1111/j.1538-7836.2008.02987.x
6. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S 2007 Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost 5:520–527. doi: 10.1111/j.1538-7836.2007.02369.x
7. Pollyea DA, Kohrt HE, Medeiros BC. Acute myeloid leukaemia in the elderly: a review. Br J Haematol 152:524–542
8. Schneider P, Van Dreden P, Rousseau A, Kassim Y, Legrand E, Vannier JP, Vasse M. Increased levels of tissue factor activity and procoagulant phospholipids during treatment of children with acute lymphoblastic leukaemia. Br J Haematol 148:582–592
9. Gheldof D, Mullier F, Bailly N, Devalet B, Dogne JM, Chatelain B, Chatelain C (2014) Microparticle bearing tissue factor: a link between promyelocytic cells and hypercoagulable state. Thromb Res 133:433–439. doi: 10.1016/j.thromres.2013.11.008
10. Furie B, Furie BC (2008) Mechanisms of thrombus formation. New Engl J Med 359:938–949. doi: 10.1056/NEJMra0801082
11. Mackman N (2004) Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 24:1015–1022. doi: 10.1161/01.ATV.0000130465.23430.74
12. Zhou J, Shi J, Hou J, Cao F, Zhang Y, Rasmussen JT, Heegaard CW, Gilbert GE (2010) Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost 8:773–782. doi: 10.1111/j.1538-7836.2010.03763.x
13. Thaler J, Pabinger I, Sperr WR, Ay C (2014) Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res 133:303–305. doi: 10.1016/j.thromres.2013.12.029
14. Issman L, Brenner B, Talmon Y, Aharon A (2013) Cryogenic transmission electron microscopy nanostructural study of shed microparticles. PloS ONE 8:e83680
15. Waisman D, Danino D, Weintraub Z, Schmidt J, Talmon Y (2007) Nanostructure of the aqueous form of lung surfactant of different species visualized by cryo-transmission electron microscopy. Clin Physiol Funct Imaging 27:375–380
16. Tatischeff I, Larquet E, Falcon-Perez JM, Turpin PY, Kruglik SG (2012) Fast characterisation of cell-derived extracellular vesicles by nanoparticles tracking analysis, cryo-electron microscopy, and Raman tweezers microspectroscopy. J Extracell Vesicles. doi: 10.3402/jev.v1i0.19179
17. Gheldof D, Hardij J, Cecchet F, Chatelain B, Dogne JM, Mullier F (2013) Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles. J Extracell Vesicles. doi: 10.3402/jev.v2i0.19728
18. Gheldof D, Mullier F, Chatelain B, Dogne JM, Chatelain C (2013) Inhibition of tissue factor pathway inhibitor increases the sensitivity of thrombin generation assay to procoagulant microvesicles. Blood Coagul Fibrinolysis 24:567–572. doi: 10.1097/MBC.0b013e328360a56e
19. Walter RB, Othus M, Burnett AK, Lowenberg B, Kantarjian HM, Ossenkoppele GJ, Hills RK, van Montfort KG, Ravandi F, Evans A, Pierce SR, Appelbaum FR, Estey EH (2013) Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 121:2424–2431. doi: 10.1182/blood-2012-10-462440
20. Carrier M, Khorana AA, Zwicker JI, Noble S, Lee AY (2014) Subcommittee on H, Malignancy for the SSCotI. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a reply to a rebuttal. J Thromb Haemost 12:116–117. doi: 10.1111/jth.12444
21. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S, Subcommittee on Control of A (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13:2119–2126
22. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M, Scientific Subcommittee on Disseminated Intravascular Coagulation of the International Society on T, Haemostasis (2001) Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86:1327–1330
23. Knobl PN (2005) On the evaluation of the ISTH score for overt disseminated intravascular coagulation. Crit Care Med 33:1185–1186
24. Schultz KR, Massing B, Spinelli JJ, Gaynon PS, Wadsworth L (1997) Importance of the day 7 bone marrow biopsy as a prognostic measure of the outcome in children with acute lymphoblastic leukemia. Med Pediatr Oncol 29:16–22
25. Robert S, Ghiotto J, Pirotte B, David JL, Masereel B, Pochet L, Dogne JM (2009) Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?. Pharmacol Res 59:160–166. doi: 10.1016/j.phrs.2008.12.003
26. Mullier F, Bailly N, Chatelain C, Chatelain B, Dogne JM (2013) Pre-analytical issues in the measurement of circulating microparticles: current recommendations and pending questions. J Thromb Haemost 11(4):693–696
27. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S (2002) The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 32: 249–253
28. Khorana AA, Connolly GC (2009) Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 27:4839–4847. doi: 10.1200/JCO.2009.22.3271
29. Owens AP 3rd, Mackman N (2012) Microparticles in hemostasis and thrombosis. Circ Res 108:1284–1297
30. Lima LG, Oliveira AS, Campos LC, Bonamino M, Chammas R, Werneck C, Vicente CP, Barcinski MA, Petersen LC, Monteiro RQ (2011) Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thromb Haemost 106:712–723
31. Li M, Yu D, Williams KJ, Liu ML (2010) Tobacco smoke induces the generation of procoagulant microvesicles from human monocytes/macrophages. Arterioscler Thromb Vasc Biol 30:1818–1824
32. Van Aalderen MC, Trappenburg MC, Van Schilfgaarde M, Molenaar PJ, Ten Cate H, Terpstra WE, Leyte A (2011) Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost 9:223–226. doi: 10.1111/j.1538-7836.2010.04133.x
33. Langer F, Amirkhosravi A, Loges S, Meyer T, Eifrig B, Hossfeld DK, Fiedler W, Francis JL (2004) An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF. Thromb Haemost 92:1136–1146
34. Langer F, Ruf W (2014) Synergies of phosphatidylserine and protein disulfide isomerase in tissue factor activation. Thromb Haemost. 111:590–597
35. Tormoen GW, Recht O, Gruber A, Levine RL, McCarty OJ (2013) Phosphatidylserine index as a marker of the procoagulant phenotype of acute myelogenous leukemia cells. Phys Biol 10:056010
36. Marchetti M, Russo L, Balducci D, Falanga A (2011) All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells. Thromb Res 128:368–374
37. Zhang XH, Hu Y, Hong M, Xia LH, Guo T, Shen GX, Wei WN, Song SJ (2007) Effects of arsenic trioxide or retinoic acid on mRNA and protein expression of tissue factor and thrombomodulin and procoagulant activity in NB4 cells. J Exp Hematol Chin Assoc Pathophysiol 15:391–395
38. Hellum M, Ovstebo R, Troseid AM, Berg JP, Brandtzaeg P, Henriksson CE (2012) Microparticle-associated tissue factor activity measured with the Zymuphen MP-TF kit and the calibrated automated thrombogram assay. Blood Coagul 23: 520–526. doi: 10.1097/MBC.0b013e328354a256
39. Tatsumi K, Antoniak S, Monroe DM, Khorana AA, Mackman N, Subcommittee on H, Malignancy of the S, Standardization Committee of the International Society on T, Hemostasis (2014) Evaluation of a new commercial assay to measure microparticle tissue factor activity in plasma: communication from the SSC of the ISTH. J Thromb Haemost 12:1932–1934. doi: 10.1111/jth.12718
40. Gheldof D, Chatelain C, Dogne JM, Mullier F (2014) Microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res 134: 213–214. doi: 10.1016/j.thromres.2014.05.001